RM Global, an Israel-based investment banking, fund management, and strategic advisory firm, announced the closing of its biopharma investment fund, at US$64M.
The additional capital, coming from institutional, family office and strategic life science investors from South Korea, the U.S., Europe and Israel, will continue to support the development of innovative Best-in-Class/First-in-Class biotherapeutics in areas including:
– Orphan Diseases, and
The RMGP Biopharma Investment Fund started operations following the initial closing in May 2017. To date, its portfolio consists of 11 companies, representing investments in both seed and follow-on rounds, including the recent BiomX Series B financing.
Managed by RM Global (RMG), the fund focuses on investing in innovative life science technologies with a global perspective. The firm’s portfolio focuses on biotherapeutics developed within the Israel-based FutuRx incubator, established by OrbiMed Israel, Johnson & Johnson Innovation, and Takeda Ventures – in cooperation with the Israel Innovation Authority (IIA).